in HCC with TP53 mutation. We then selected Nultin-3, which has been investigated as a potential therapeutic agent specifically targeting TP53-mutated cancer cells [16]. Furthermore, we further supplemented with 10 μM Nultin-3 in the previous knockout of CHEK2 HCC cell lines (LM3, Huh...
The eQTLgen database and two HCC Genome-Wide Association Study (GWAS) datasets (ieu-b-4953, ICD10 C22.0) were used to find the drug target: CHEK2. Next, Colony, Edu, 尾-gal, and cell cycle analysis were facilitated to evaluate the role of CHEK2 knockout in HCC. In addition, Nul...
The presence of both HPV infection and TP53 mutations may define a particular group of tumors with a more aggressive phenotype in advanced OSCC.Keywords Oral cancer, HPV infection, TP53 mutation, Disease-free intervalReferencesSection:1. Zur Hausen, H.. Papillomaviruses and cancer: from basic ...
IDH1 mutation status, p53 expression status (p > 10% is considered 'high') and 1p/19q co-deletion status were significantly different among TP53 Cancers 2021, 13, 5362 8 of 28 mutant and TP53 WT groups (p = 0.009, p < 0.001 and p < 0.001, respectively). In TP53 Cancers 2021, 13...
Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study. Lancet Oncol. 2016, 17, 1295–1305. [CrossRef] 10. Levine, A.J. p53, the Cellular Gatekeeper for Growth and Division. Cell 1997, 88, ...